

Hanns-Ulrich Marschall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1123615/publications.pdf>

Version: 2024-02-01

215
papers

23,550
citations

11608

70
h-index

8370

147
g-index

223
all docs

223
docs citations

223
times ranked

21204
citing authors

#	ARTICLE	IF	CITATIONS
1	Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. <i>Cell Metabolism</i> , 2016, 24, 41-50.	7.2	1,734
2	Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist. <i>Cell Metabolism</i> , 2013, 17, 225-235.	7.2	1,671
3	Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease. <i>Transplantation</i> , 2006, 81, 1390-1397.	0.5	1,003
4	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
5	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2016, 375, 631-643.	13.9	817
6	Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2013, 145, 574-582.e1.	0.6	795
7	Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. <i>Hepatology</i> , 2004, 40, 467-474.	3.6	714
8	Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. <i>Nature Genetics</i> , 2016, 48, 1396-1406.	9.4	533
9	Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. <i>Gastroenterology</i> , 2004, 127, 261-274.	0.6	525
10	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. <i>Gastroenterology</i> , 2015, 148, 751-761.e8.	0.6	470
11	Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. <i>Journal of Hepatology</i> , 2000, 33, 1012-1021.	1.8	456
12	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	0.6	355
13	High-Dose Ursodeoxycholic Acid in Primary Sclerosing Cholangitis: A 5-Year Multicenter, Randomized, Controlled Study. <i>Gastroenterology</i> , 2005, 129, 1464-1472.	0.6	343
14	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , 2013, 45, 670-675.	9.4	339
15	An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans. <i>Cell Metabolism</i> , 2018, 27, 559-571.e5.	7.2	321
16	The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. <i>Gut</i> , 2017, 66, 611-619.	6.1	308
17	Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. <i>Lancet, The</i> , 2019, 393, 899-909.	6.3	305
18	Role of Bile Acids in Metabolic Control. <i>Trends in Endocrinology and Metabolism</i> , 2018, 29, 31-41.	3.1	299

#	ARTICLE	IF	CITATIONS
19	CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. <i>Hepatology</i> , 2005, 42, 420-430.	3.6	295
20	A New Xenobiotic-Induced Mouse Model of Sclerosing Cholangitis and Biliary Fibrosis. <i>American Journal of Pathology</i> , 2007, 171, 525-536.	1.9	293
21	Role of Nuclear Receptors in the Adaptive Response to Bile Acids and Cholestasis: Pathogenetic and Therapeutic Considerations. <i>Molecular Pharmaceutics</i> , 2006, 3, 231-251.	2.3	288
22	Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangiocytes. <i>Gastroenterology</i> , 2002, 123, 1238-1251.	0.6	287
23	24-norUrsodeoxycholic Acid Is Superior to Ursodeoxycholic Acid in the Treatment of Sclerosing Cholangitis in Mdr2 (Abcb4) Knockout Mice. <i>Gastroenterology</i> , 2006, 130, 465-481.	0.6	282
24	Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans. <i>Gastroenterology</i> , 2005, 129, 476-485.	0.6	268
25	Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2003, 38, 717-727.	1.8	260
26	Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. <i>Gastroenterology</i> , 2003, 125, 825-838.	0.6	252
27	Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. <i>Journal of Hepatology</i> , 2015, 62, 1398-1404.	1.8	236
28	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 269-273.	9.4	230
29	Intrahepatic cholestasis of pregnancy: A randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. <i>Hepatology</i> , 2005, 42, 1399-1405.	3.6	226
30	Genetic and environmental influences on symptomatic gallstone disease: A Swedish study of 43,141 twin pairs. <i>Hepatology</i> , 2005, 41, 1138-1143.	3.6	221
31	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. <i>Hepatology</i> , 2018, 67, 1890-1902.	3.6	204
32	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 549-558.	1.8	202
33	Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 717-723.	1.1	200
34	Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. <i>Journal of Hepatology</i> , 2012, 57, 366-375.	1.8	196
35	Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. <i>Gut</i> , 2009, 58, 537-544.	6.1	179
36	Germline selection shapes human mitochondrial DNA diversity. <i>Science</i> , 2019, 364, .	6.0	178

#	ARTICLE	IF	CITATIONS
37	Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: A population-based cohort study. <i>Hepatology</i> , 2013, 58, 1385-1391.	3.6	177
38	Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. <i>Journal of Hepatology</i> , 2003, 39, 480-488.	1.8	171
39	FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. <i>Cell Metabolism</i> , 2021, 33, 1671-1684.e4.	7.2	165
40	Lithocholic Acid Feeding Induces Segmental Bile Duct Obstruction and Destructive Cholangitis in Mice. <i>American Journal of Pathology</i> , 2006, 168, 410-422.	1.9	161
41	Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. <i>Journal of Hepatology</i> , 2006, 44, 768-775.	1.8	158
42	Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-1 [±] /2 in the adaptive response to bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G923-G932.	1.6	154
43	Gallstone disease. <i>Journal of Internal Medicine</i> , 2007, 261, 529-542.	2.7	151
44	Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at <i>GPR35</i> and <i>TCF4</i> . <i>Hepatology</i> , 2013, 58, 1074-1083.	3.6	150
45	Personal model-assisted identification of NAD ⁺ and glutathione metabolism as intervention target in NAFLD. <i>Molecular Systems Biology</i> , 2017, 13, 916.	3.2	147
46	Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype. <i>Hepatology</i> , 2013, 57, 716-726.	3.6	146
47	Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. <i>Journal of Hepatology</i> , 2016, 64, 674-681.	1.8	143
48	Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in <i>Mdr2^{-/-}</i> mice. <i>Hepatology</i> , 2009, 49, 1972-1981.	3.6	135
49	Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1688-1697.	2.0	131
50	Characterization of animal models for primary sclerosing cholangitis (PSC). <i>Journal of Hepatology</i> , 2014, 60, 1290-1303.	1.8	129
51	Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. <i>Gut</i> , 2019, 68, 1477-1492.	6.1	128
52	Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. <i>Gut</i> , 2007, 56, 265-270.	6.1	122
53	Chronic liver disease is triggered by taurine transporter knockout in the mouse. <i>FASEB Journal</i> , 2006, 20, 574-576.	0.2	106
54	A Comprehensive Analysis of Common Genetic Variation Around Six Candidate Loci for Intrahepatic Cholestasis of Pregnancy. <i>American Journal of Gastroenterology</i> , 2014, 109, 76-84.	0.2	103

#	ARTICLE	IF	CITATIONS
55	Intrahepatic cholestasis of pregnancy: Amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. <i>Hepatology</i> , 2008, 47, 544-551.	3.6	102
56	Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. <i>Hepatology</i> , 2016, 64, 189-199.	3.6	101
57	Fxr ^{-/-} mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. <i>Journal of Lipid Research</i> , 2006, 47, 582-592.	2.0	98
58	Fish protein hydrolysate elevates plasma bile acids and reduces visceral adipose tissue mass in rats. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 254-262.	1.2	98
59	Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study. <i>Journal of Hepatology</i> , 2015, 63, 456-461.	1.8	98
60	Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. <i>Hepatology</i> , 2010, 52, 197-203.	3.6	95
61	Expanded substrate screenings of human and Drosophila type 10 17 β -hydroxysteroid dehydrogenases (HSDs) reveal multiple specificities in bile acid and steroid hormone metabolism: characterization of multifunctional 3 α /7 α /7 β /17 β /20 β /21-HSD. <i>Biochemical Journal</i> , 2003, 376, 49-60.	1.7	87
62	Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. <i>Hepatology</i> , 2016, 63, 1287-1298.	3.6	85
63	Bile acid N-acetylglucosaminidation. In vivo and in vitro evidence for a selective conjugation reaction of 7 beta-hydroxylated bile acids in humans. <i>Journal of Clinical Investigation</i> , 1992, 89, 1981-1987.	3.9	85
64	Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1950-1956.e1.	2.4	84
65	The Reversed Feto-Maternal Bile Acid Gradient in Intrahepatic Cholestasis of Pregnancy Is Corrected by Ursodeoxycholic Acid. <i>PLoS ONE</i> , 2014, 9, e83828.	1.1	84
66	Stimulation of bile acid 6 α -hydroxylation by rifampin. <i>Journal of Hepatology</i> , 1996, 24, 713-718.	1.8	83
67	Oncosis represents the main type of cell death in mouse models of cholestasis. <i>Journal of Hepatology</i> , 2005, 42, 378-385.	1.8	80
68	Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 189, 59-63.	0.5	80
69	Crosstalk between Bile Acids and Gut Microbiota and Its Impact on Farnesoid X Receptor Signalling. <i>Digestive Diseases</i> , 2017, 35, 246-250.	0.8	80
70	The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 303-310.	1.9	74
71	Life-threatening complications of nasogastric administration of polyethylene glycol-electrolyte solutions (Golytely) for bowel cleansing. <i>Gastrointestinal Endoscopy</i> , 1998, 47, 408-410.	0.5	72
72	Endoscopic assessment and grading of Barrett's esophagus using magnification endoscopy and narrow-band imaging: accuracy and interobserver agreement of different classification systems (with Tj ETQq0 0 0gBT /Overlock 10 TF		

#	ARTICLE	IF	CITATIONS
73	Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 1257-1264.	0.6	71
74	No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2018, 155, 752-759.e5.	0.6	69
75	Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. <i>Nature Communications</i> , 2022, 13, .	5.8	68
76	Induction of farnesoid X receptor signaling in germ-free mice colonized with a human microbiota. <i>Journal of Lipid Research</i> , 2017, 58, 412-419.	2.0	66
77	Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling. <i>Nature Metabolism</i> , 2021, 3, 1228-1241.	5.1	65
78	Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. <i>Scientific Reports</i> , 2018, 8, 6658.	1.6	61
79	Gallstone disease in Swedish twins: risk is associated with <i>ABCG8</i> D19H genotype. <i>Journal of Internal Medicine</i> , 2010, 268, 279-285.	2.7	60
80	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 159-165.	0.6	60
81	Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 547-558.	3.7	60
82	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 179-187.e6.	2.4	57
83	Outcomes of Pregnancy in Mothers With Cirrhosis: A National Population-Based Cohort Study of 1.3 Million Pregnancies. <i>Hepatology Communications</i> , 2018, 2, 1299-1305.	2.0	56
84	Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH. <i>Frontiers in Pharmacology</i> , 2018, 9, 931.	1.6	56
85	Nutritional Regulation of Bile Acid Metabolism Is Associated with Improved Pathological Characteristics of the Metabolic Syndrome. <i>Journal of Biological Chemistry</i> , 2011, 286, 28382-28395.	1.6	55
86	Inhibition of Na ⁺ -Taurocholate Co-transporting Polypeptide-mediated Bile Acid Transport by Cholestatic Sulfated Progesterone Metabolites. <i>Journal of Biological Chemistry</i> , 2010, 285, 16504-16512.	1.6	54
87	Colesevelam attenuates cholestatic liver and bile duct injury in <i>Mdr2</i> ^{-/-} mice by modulating composition, signalling and excretion of faecal bile acids. <i>Gut</i> , 2018, 67, 1683-1691.	6.1	53
88	AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 67-80.	1.5	52
89	Metabolic preconditioning protects BSEP/ABCB11 ^{-/-} mice against cholestatic liver injury. <i>Journal of Hepatology</i> , 2017, 66, 95-101.	1.8	51
90	Associations between Dietary Patterns and Bile Acids—Results from a Cross-Sectional Study in Vegans and Omnivores. <i>Nutrients</i> , 2020, 12, 47.	1.7	50

#	ARTICLE	IF	CITATIONS
91	Body mass index, alcohol, tobacco and symptomatic gallstone disease: a Swedish twin study. <i>Journal of Internal Medicine</i> , 2007, 262, 581-587.	2.7	49
92	FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis. <i>Journal of Hepatology</i> , 2020, 72, 1122-1131.	1.8	47
93	Enhanced Microbial Bile Acid Deconjugation and Impaired Ileal Uptake in Pregnancy Repress Intestinal Regulation of Bile Acid Synthesis. <i>Hepatology</i> , 2019, 70, 276-293.	3.6	46
94	Evidence for bile acid glucosides as normal constituents in human urine. <i>FEBS Letters</i> , 1987, 213, 411-414.	1.3	45
95	The major metabolites of ursodeoxycholic acid in human urine are conjugated with N-acetylglucosamine. <i>Hepatology</i> , 1994, 20, 845-853.	3.6	45
96	NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. <i>Journal of Hepatology</i> , 2017, 67, 110-119.	1.8	44
97	Obeticholic acid may increase the risk of gallstone formation in susceptible patients. <i>Journal of Hepatology</i> , 2019, 71, 986-991.	1.8	44
98	Intrahepatic cholestasis of pregnancy. <i>Current Treatment Options in Gastroenterology</i> , 2003, 6, 123-132.	0.3	42
99	Hep27, a member of the short-chain dehydrogenase/reductase family, is an NADPH-dependent dicarbonyl reductase expressed in vascular endothelial tissue. <i>Cellular and Molecular Life Sciences</i> , 2006, 63, 1205-1213.	2.4	42
100	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1517-1524.	6.1	42
101	STK25 is a critical determinant in nonalcoholic steatohepatitis. <i>FASEB Journal</i> , 2016, 30, 3628-3643.	0.2	41
102	Decreased 1,25-dihydroxy vitamin D levels in women with intrahepatic cholestasis of pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010, 89, 1420-1423.	1.3	39
103	The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against nonalcoholic fatty liver disease. <i>Molecular Systems Biology</i> , 2020, 16, e9495.	3.2	39
104	Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort. <i>Scientific Reports</i> , 2019, 9, 11525.	1.6	38
105	Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations. <i>Journal of Hepatology</i> , 2021, 74, 1087-1096.	1.8	38
106	Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 936-942.	1.4	37
107	6 β -hydroxylated bile acids mediate TGR5 signalling to improve glucose metabolism upon dietary fiber supplementation in mice. <i>Gut</i> , 2023, 72, 314-324.	6.1	36
108	6 β -Glucuronidation of hyodeoxycholic acid by human liver, kidney and small bowel microsomes. <i>Lipids and Lipid Metabolism</i> , 1987, 921, 392-397.	2.6	35

#	ARTICLE	IF	CITATIONS
109	Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. <i>Hepatology Communications</i> , 2018, 2, 69-83.	2.0	35
110	Role of short-chain hydroxyacyl CoA dehydrogenases in SCHAD deficiency. <i>Biochemical and Biophysical Research Communications</i> , 2008, 368, 6-11.	1.0	34
111	The genetic background of gallstone formation: An update. <i>Biochemical and Biophysical Research Communications</i> , 2010, 396, 58-62.	1.0	34
112	Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1101-1108.	0.2	34
113	High clinical impact and diagnostic accuracy of EUS-guided biopsy sampling of subepithelial lesions: a prospective, comparative study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 1304-1313.	1.3	33
114	Isolation of bile acid glucosides and N-acetylglucosaminides from human urine by ion-exchange chromatography and reversed-phase high-performance liquid chromatography. <i>Journal of Chromatography A</i> , 1988, 452, 459-468.	1.8	32
115	Urinary excretion of bile acid glucosides and glucuronides in extrahepatic cholestasis. <i>Hepatology</i> , 1991, 13, 656-662.	3.6	32
116	The influence of rifampin treatment on caffeine clearance in healthy man. <i>Journal of Hepatology</i> , 1995, 22, 78-81.	1.8	32
117	Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. <i>Journal of Hepatology</i> , 2006, 44, 243-245.	1.8	32
118	Stereological assessment of placental morphology in intrahepatic cholestasis of pregnancy. <i>Placenta</i> , 2012, 33, 914-918.	0.7	32
119	Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-7.	0.6	32
120	Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 597-618.	2.3	32
121	Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis. <i>Journal of Lipid Research</i> , 2001, 42, 735-742.	2.0	32
122	Endoscopic assessment and grading of Barrett's esophagus using magnification endoscopy and narrow band imaging: Impact of structured learning and experience on the accuracy of the Amsterdam classification system. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 160-167.	0.6	30
123	Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019, 126, 1633-1640.	1.1	29
124	Management of intrahepatic cholestasis of pregnancy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1273-1279.	1.4	28
125	Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. <i>Liver International</i> , 2018, 38, 523-531.	1.9	28
126	Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial. <i>BMC Gastroenterology</i> , 2018, 18, 76.	0.8	28

#	ARTICLE	IF	CITATIONS
127	Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy. <i>Scientific Reports</i> , 2020, 10, 3895.	1.6	27
128	Analysis of ileal sodium/bile acid cotransporter and related nuclear receptor genes in a family with multiple cases of idiopathic bile acid malabsorption. <i>World Journal of Gastroenterology</i> , 2006, 12, 7710.	1.4	27
129	Recent advances on FXR-targeting therapeutics. <i>Molecular and Cellular Endocrinology</i> , 2022, 552, 111678.	1.6	27
130	Human liver class I alcohol dehydrogenase ³ isozyme: the sole cytosolic 3 ² -hydroxysteroid dehydrogenase of iso bile acids. <i>Hepatology</i> , 2000, 31, 990-996.	3.6	26
131	Serum bile acids and GLP-1 decrease following telemetric induced weight loss: results of a randomized controlled trial. <i>Scientific Reports</i> , 2016, 6, 30173.	1.6	26
132	A new subgroup of lectin-bound biliary proteins binds to cholesterol crystals, modifies crystal morphology, and inhibits cholesterol crystallization.. <i>Journal of Clinical Investigation</i> , 1995, 96, 3009-3015.	3.9	25
133	Protein kinase STK25 aggravates the severity of non-alcoholic fatty pancreas disease in mice. <i>Journal of Endocrinology</i> , 2017, 234, 15-27.	1.2	23
134	Lipid droplet-associated kinase STK25 regulates peroxisomal activity and metabolic stress response in steatotic liver. <i>Journal of Lipid Research</i> , 2020, 61, 178-191.	2.0	23
135	Portal Vein Thrombosis after Occlusion of a Transjugular Intrahepatic Portosystemic Shunt: Recanalization with the Impeller Catheter. <i>Journal of Vascular and Interventional Radiology</i> , 1994, 5, 467-471.	0.2	22
136	Clinical Hepatotoxicity. Regulation and Treatment with Inducers of Transport and Cofactors. <i>Molecular Pharmaceutics</i> , 2007, 4, 895-910.	2.3	22
137	Risks of emergency cesarean section and fetal asphyxia after induction of labor in intrahepatic cholestasis of pregnancy: A hospital-based retrospective cohort study. <i>Sexual and Reproductive Healthcare</i> , 2013, 4, 17-22.	0.5	22
138	Epidermal growth factor signaling protects from cholestatic liver injury and fibrosis. <i>Journal of Molecular Medicine</i> , 2017, 95, 109-117.	1.7	21
139	A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC randomised trial. <i>BMC Pregnancy and Childbirth</i> , 2021, 21, 51.	0.9	21
140	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	1.8	21
141	Pregnancy outcome in women undergoing liver biopsy during pregnancy: A nationwide population-based cohort study. <i>Hepatology</i> , 2018, 68, 625-633.	3.6	20
142	Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans. <i>FASEB Journal</i> , 2019, 33, 9974-9989.	0.2	20
143	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2295-2304.e2.	2.4	18
144	Study of human isoursodeoxycholic acid metabolism. <i>Journal of Hepatology</i> , 1997, 26, 863-870.	1.8	17

#	ARTICLE	IF	CITATIONS
145	Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders. <i>Biochemical Society Transactions</i> , 2022, 50, 361-373.	1.6	16
146	Bile acid N-acetylglucosaminides. <i>FEBS Letters</i> , 1990, 270, 11-14.	1.3	15
147	Large expert-curated database for benchmarking document similarity detection in biomedical literature search. <i>Database: the Journal of Biological Databases and Curation</i> , 2019, 2019, .	1.4	15
148	Silencing of STE20-type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet-induced nonalcoholic fatty liver disease. <i>FASEB Journal</i> , 2021, 35, e21567.	0.2	15
149	Absence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice. <i>Liver International</i> , 2020, 40, 1366-1377.	1.9	14
150	Depletion of protein kinase STK25 ameliorates renal lipotoxicity and protects against diabetic kidney disease. <i>JCI Insight</i> , 2020, 5, .	2.3	14
151	Long-Term Extracorporeal Bilirubin Elimination: A Case Report on Cascade Resin Plasma perfusion. <i>Blood Purification</i> , 1998, 16, 341-348.	0.9	13
152	Cyp3a11 is not essential for the formation of murine bile acids. <i>Biochemistry and Biophysics Reports</i> , 2017, 10, 70-75.	0.7	13
153	Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis. <i>Medicine (United States)</i> , 2017, 96, e7708.	0.4	13
154	STE20-type Protein Kinase MST4 Controls NAFLD Progression by Regulating Lipid Droplet Dynamics and Metabolic Stress in Hepatocytes. <i>Hepatology Communications</i> , 2021, 5, 1183-1200.	2.0	13
155	Hepatocyte specific expression of an oncogenic variant of β -catenin results in cholestatic liver disease. <i>Oncotarget</i> , 2016, 7, 86985-86998.	0.8	13
156	Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2001, 1526, 44-52.	1.1	12
157	Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications?. <i>Current Hepatology Reports</i> , 2017, 16, 119-123.	0.4	12
158	Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: Case series and mechanism of action. <i>Journal of Clinical Apheresis</i> , 2018, 33, 638-644.	0.7	12
159	STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1723-1737.	1.1	12
160	Bile acid biosynthesis in Smith-Lemli-Opitz syndrome bypassing cholesterol: Potential importance of pathway intermediates. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 206, 105794.	1.2	12
161	When Bile Acids Don't Get Amidated. <i>Gastroenterology</i> , 2013, 144, 870-873.	0.6	11
162	Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E399-E410.	1.8	11

#	ARTICLE	IF	CITATIONS
163	Maternal glucose homeostasis is impaired in mouse models of gestational cholestasis. <i>Scientific Reports</i> , 2020, 10, 11523.	1.6	11
164	Morbidity, risk of cancer and mortality in 3645 <i>HFE</i> mutations carriers. <i>Liver International</i> , 2021, 41, 545-553.	1.9	11
165	Gallstone disease in Swedish twins is associated with the Gilbert variant of <i>UGT</i> 1A1. <i>Liver International</i> , 2013, 33, 904-908.	1.9	10
166	Ursodeoxycholic acid improves fetoplacental and offspring metabolic outcomes in hypercholanemic pregnancy. <i>Scientific Reports</i> , 2020, 10, 10361.	1.6	10
167	Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 405-423.	2.3	10
168	STE20-type kinase TAOK3 regulates hepatic lipid partitioning. <i>Molecular Metabolism</i> , 2021, 54, 101353.	3.0	10
169	Synthesis of ¹³ C-labeled chenodeoxycholic, hyodeoxycholic, and ursodeoxycholic acids for the study of bile acid metabolism in liver disease. <i>Clinica Chimica Acta</i> , 1991, 203, 77-89.	0.5	9
170	Enteral donor pre-treatment with ursodeoxycholic acid protects the liver against ischaemia-reperfusion injury in rats. <i>Transplant International</i> , 2004, 17, 804-809.	0.8	9
171	Angiotensin II exerts dual actions on sodium-glucose transporter 1-mediated transport in the human jejunal mucosa. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1068-1075.	0.6	9
172	Ursodeoxycholic Acid for Treatment of Fatty Liver Disease and Dyslipidemia in Morbidly Obese Patients. <i>Digestive Diseases</i> , 2011, 29, 117-118.	0.8	8
173	Ursodeoxycholic acid for intrahepatic cholestasis in pregnancy. <i>Lancet</i> , The, 2019, 394, 810-812.	6.3	8
174	Increase in renal glutathione in cholestatic liver disease is due to a direct effect of bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 283, F1281-F1289.	1.3	7
175	The 35-year odyssey of beta blockers in cirrhosis: any gender difference in sight?. <i>Pharmacological Research</i> , 2017, 119, 20-26.	3.1	7
176	Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G197-G211.	1.6	7
177	Bioinformatics in Studies of SDR and MDR Enzymes. <i>Advances in Experimental Medicine and Biology</i> , 1999, 463, 373-377.	0.8	7
178	Enteral donor pre-treatment with ursodeoxycholic acid protects the liver against ischaemia-reperfusion injury in rats. <i>Transplant International</i> , 2005, 17, 804-9.	0.8	6
179	Combined Rifampicin and Ursodeoxycholic Acid Treatment Does Not Amplify Rifampicin Effects on Hepatic Detoxification and Transport Systems in Humans. <i>Digestion</i> , 2012, 86, 244-249.	1.2	6
180	Variant adiponutrin confers genetic protection against cholestatic itch. <i>Scientific Reports</i> , 2015, 4, 6374.	1.6	6

#	ARTICLE	IF	CITATIONS
181	Could gut microbiota protect against sclerosing cholangitis?. <i>Hepatology</i> , 2016, 63, 26-27.	3.6	6
182	Muscle performance and fatigue in compensated chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 925-933.	0.6	6
183	Future Medical Treatment of PSC. <i>Current Hepatology Reports</i> , 2019, 18, 96-106.	0.4	6
184	Association of Adverse Perinatal Outcomes of Intrahepatic Cholestasis of Pregnancy With Biochemical Markers: Results of Aggregate and Individual Patient Data Meta-analyses. <i>Obstetrical and Gynecological Survey</i> , 2019, 74, 388-390.	0.2	6
185	Inhibition of MAP4K4 signaling initiates metabolic reprogramming to protect hepatocytes from lipotoxic damage. <i>Journal of Lipid Research</i> , 2022, 63, 100238.	2.0	6
186	Primary cultures of human hepatocytes but not HepG2 hepatoblastoma cells are suitable for the study of glycosidic conjugation of bile acids. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2001, 1530, 155-161.	1.2	5
187	Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 481-487.	0.8	5
188	Plasma Bile Acid Concentrations in Humans: Suggestions for Presentation in Tabular Form. <i>Hepatology</i> , 2018, 68, 787-787.	3.6	5
189	Meta-analysis and Consolidation of Farnesoid X Receptor Chromatin Immunoprecipitation Sequencing Data Across Different Species and Conditions. <i>Hepatology Communications</i> , 2021, 5, 1721-1736.	2.0	5
190	Ring Trial on Quantitative Assessment of Bile Acids Reveals a Method- and Analyte-Specific Accuracy and Reproducibility. <i>Metabolites</i> , 2022, 12, 583.	1.3	5
191	Reply:. <i>Hepatology</i> , 2005, 42, 738-738.	3.6	4
192	Fibroblast growth factor 21 signaling: The liver in focus. <i>Hepatology</i> , 2016, 64, 333-335.	3.6	4
193	The BACH project protocol: an international multicentre total Bile Acid Comparison and Harmonisation project and sub-study of the TURREFIC randomised trial. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1921-1929.	1.4	4
194	Impact of gastroesophageal reflux control through tailored proton pump inhibition therapy or fundoplication in patients with Barrett's esophagus. <i>World Journal of Gastroenterology</i> , 2017, 23, 3174.	1.4	4
195	Silencing of STE20-type kinase STK25 in human aortic endothelial and smooth muscle cells is atheroprotective. <i>Communications Biology</i> , 2022, 5, 379.	2.0	4
196	Glycemic Control and Metabolic Adaptation in Response to High-Fat versus High-Carbohydrate Diets—Data from a Randomized Cross-Over Study in Healthy Subjects. <i>Nutrients</i> , 2021, 13, 3322.	1.7	3
197	A Fatty Diet Induces a Jejunal Ketogenesis Which Inhibits Local SGLT1-Based Glucose Transport via an Acetylation Mechanism—Results from a Randomized Cross-Over Study between Iso-Caloric High-Fat versus High-Carbohydrate Diets in Healthy Volunteers. <i>Nutrients</i> , 2022, 14, 1961.	1.7	3
198	Pregnancy course in patients with intrahepatic cholestasis of pregnancy treated with very low doses of ursodeoxycholic acid. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 256-256.	0.6	2

#	ARTICLE	IF	CITATIONS
199	Response. <i>Gastrointestinal Endoscopy</i> , 1999, 49, 818-819.	0.5	1
200	Basolateral hepatic export of bile acid glucuronides via MRP3: An important route for bile acid detoxification?. <i>Gastroenterology</i> , 2003, 124, A698.	0.6	1
201	Ensuring timely treatment of patients with primary biliary cholangitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 591-593.	3.7	1
202	Reply. <i>Hepatology Communications</i> , 2019, 3, 848-848.	2.0	1
203	THU-007-Absence of BSEP (ABCB11) protects MDR2 (ABCB4) KO mice from cholestatic liver and bile duct injury through anti-inflammatory bile acid composition and signaling. <i>Journal of Hepatology</i> , 2019, 70, e163-e164.	1.8	1
204	Gut pathobionts as triggers for liver diseases. <i>Nature Microbiology</i> , 2019, 4, 380-381.	5.9	1
205	A Comprehensive FXR Signaling Atlas Derived from Pooled ChIP-seq Data. <i>Studies in Health Technology and Informatics</i> , 2019, 260, 105-112.	0.2	1
206	Renal function after liver transplantation: Real-world experience with basiliximab induction and delayed reduced-dose tacrolimus. <i>Digestive and Liver Disease</i> , 2022, 54, 1076-1083.	0.4	1
207	Cultured human hepatocytes but not HepG2 are suitable for the study of bile acid conjugation. <i>Gastroenterology</i> , 2000, 118, A999.	0.6	0
208	Role of nuclear bile acid receptor, FXR, in determining ATP-binding cassette (ABC) transporter expression and cholestatic liver injury in common bile duct-ligated mice. <i>Gastroenterology</i> , 2003, 124, A697-A698.	0.6	0
209	Intrahepatic cholestasis of pregnancy: Identification of bile acid cut-off levels indicating fetal complications. <i>Gastroenterology</i> , 2003, 124, A786.	0.6	0
210	Intrahepatic Cholestasis of Pregnancy and Associated Adverse Pregnancy and Fetal Outcomes. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 783-785.	0.2	0
211	Reply. <i>Hepatology</i> , 2014, 60, 1452-1452.	3.6	0
212	746 Absence of BSEP/ABCB11 Protects From Cholestatic Liver Injury in Mice. <i>Gastroenterology</i> , 2016, 150, S1045.	0.6	0
213	Letter: ileal bile acid transporter inhibition- is there a potential for drug-drug interaction? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 751-751.	1.9	0
214	PS-159-Intestinal dysbiosis fuels liver disease progression via NLRP3 in the Mdr2 ^{-/-} mouse model of primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e100.	1.8	0
215	The Importance of Gestation-Adjusted Birthweight Centile in Assessment of Fetal Growth in Metabolic Conditions. <i>JCRPE Journal of Clinical Research in Pediatric Endocrinology</i> , 2018, 10, 299-300.	0.4	0